



BIOMMUNE, A 2016 TSX VENTURE TOP 50 COMPANY, AWARDED PATENT FOR CALCIUM CHANNEL MONOCLONAL ANTIBODIES

Vancouver, British Columbia, June 29, 2016 - bioMmune Technologies Inc. (“bioMmune” or the “Company”) (TSX.V:IMU) has been awarded its first patent for monoclonal antibodies that modulate voltage gated calcium channels in immune cells. The patent was awarded from China for a period of 20 years. Voltage gated calcium channels are validated drug targets for blood pressure, pain, and heart arrhythmia. However, all currently approved calcium channel drugs are small molecules, while bioMmune’s patent covers monoclonal antibodies specific for immune cell targets. Monoclonal antibodies offer excellent safety profiles and have several additional advantages over small molecules, including high specificity, long half life, and the ability to deliver chemical payloads to target cells.

bioMmune also holds a patent in Australia for a separate technology, novel compounds that restore immune recognition of cancer cells and aid in their destruction. bioMmune has a growing patent portfolio covering its innovative technologies and therapeutic programs.

bioMmune was among the 2016 TSX Venture 50, a ranking of the top fifty performers on the TSX Venture exchange. Of more than 2,500 listed companies, bioMmune was one of the top ten biotechnology companies. These rankings are based on market capitalization growth, share price appreciation, and trading volume. The company is pursuing therapies that activate and enhance patients’ immune systems for therapeutic purposes.

ABOUT BIOMMUNE TECHNOLOGIES INC.

bioMmune focuses on immunotherapies against cancer, infectious and autoimmune diseases. The Company’s three significant technologies are based on:

1. Utilizing proprietary screening systems for identifying novel compounds that are able to restore immune recognition and killing of cancer cells.
2. Exploiting the regulation of calcium channel activity for cells of the immune system. By regulating these calcium channels, immune activity can be improved to combat cancers, infections and autoimmune diseases.
3. Modulating CD74, a protein involved in the immune system and its ability to fight foreign antigens. Finding molecules that regulate CD74 activity will aid the immune system to combat infections and cancers and to control autoimmune diseases.

On Behalf of the Board of Directors

Dr. Patrick Gray, CEO

For more information contact:

Dr. Patrick Gray
(206) 650-6765

Forward Looking Statements

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties and other factors and may cause actual results to differ materially from current expectations. The Company does not undertake to revise any forward-looking statement to reflect events or circumstances that occur after the date of this press release.

***Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.**